Episode
Antibody-Drug Conjugates in Gynecologic Cancers — Proceedings from a Session Held During the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancer
- Podcast
- Gynecologic Oncology Update
- Published
- Jun 3, 2026
- Duration seconds
- 5475
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/gynecologic-oncology-update-612940/episodes/antibody-drug-conjugates-in-gynecologic-cancers-proceedings-from-a-session-held-during-the-society-of-gynecologic-oncology-2026-annual-meeting-on-women-s-cancer/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/gynecologic-oncology-update-612940/antibody-drug-conjugates-in-gynecologic-cancers-proceedings-from-a-session-held-during-the-society-of-gynecologic-oncology-2026-annual-meeting-on-women-s-cancer.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Prof Ramez N Eskander from UC San Diego Moores Cancer Center in California, Dr Bradley J Monk from Florida Cancer Specialists & Research Institute in West Palm Beach and Dr Kathleen N Moore from the Fred and Pamela Buffett Cancer Center in Omaha, Nebraska, review the treatment landscape of antibody-drug conjugate–directed therapy for gynecologic cancers and review recently presented clinical findings from the SGO 2026 Annual Meeting on Women’s Cancer. CME information and select publications